Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
Open Access
- 16 September 2020
- Vol. 7 (9), 140
- https://doi.org/10.3390/children7090140
Abstract
This study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (n = 13) with cancer who had been administered olanzapine as an anti-emetic drug (AED) during a high and moderate emetogenic chemotherapy block from January 2018 to March 2020. Patients were administered other prophylactic AEDs according to practice guidelines. The mean age of the patients was 14.1 ± 5.5 years. The total number of chemotherapy cycles was 41. Twenty-one (51.2%) chemotherapy blocks were high emetogenic chemotherapy and 20 (48.8%) blocks were moderate emetogenic chemotherapy. Olanzapine was used for prophylaxis in 20 (48.8%) blocks of chemotherapy and rescue in 21 (51.2%). Of the 41 cycles, a complete response to olanzapine was achieved in 31 (75.6%), partial response in 6 (14.6%), and no response in 4 (9.8%). The mean dose was 0.07 ± 0.04 mg/kg/dose and 2.50 ± 1.37 mg/m2/dose. Adverse effects included somnolence, hyperglycemia, fatigue, and disturbed sleep. Our findings indicate that olanzapine was effective and safe for treating chemotherapy-induced nausea and vomiting in children. A prospective controlled study is needed to confirm these findings.Funding Information
- Yeungnam University (220A480014)
This publication has 22 references indexed in Scilit:
- Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Olanzapine for treatment and prevention of acute chemotherapy‐induced vomiting in children: A retrospective, multi‐center reviewPediatric Blood & Cancer, 2014
- The Safety of Olanzapine in Young Children: A Systematic Review and Meta-AnalysisDrug Safety, 2014
- Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2013
- The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapySupportive Care in Cancer, 2013
- Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III TrialThe Journal of Supportive Oncology, 2011
- Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patientsPediatric Blood & Cancer, 2011
- Olanzapine for the treatment of bipolar disorder in children and adolescentsExpert Opinion on Pharmacotherapy, 2008
- A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group studySupportive Care in Cancer, 2007
- A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group studySupportive Care in Cancer, 2005